Sub-analysis | Studies (N) | Participants (N) | Pooled non-specific anxiety prevalence (%) | Lower 95% CI | Upper 95% CI | Heterogeneity (I2) |
---|---|---|---|---|---|---|
Outcome measure | ||||||
 DASS-Aa | 37 | 34606 | 52.10% | 45.78 | 58.42 | 99.33%* |
 GAD-7 | 13 | 9564 | 30.27% | 20.41 | 40.12 | 99.47%* |
 BAI | 12 | 5448 | 36.29% | 29.45 | 43.12 | 96.50%* |
 HADS-A | 6 | 2156 | 37.20% | 28.77 | 45.64 | 94.04%* |
 SAS | 4 | 45789 | 16.47% | 8.25 | 24.7 | 99.41%* |
 BSI-ANG | 2 | 2131 | 27.64% | 25.74 | 29.54 | n/a |
 SCL-90-A | 2 | 1071 | 14.83% | 12.73 | 16.92 | n/a |
 PHQ-A | 2 | 2273 | 0.36% | 0.12 | 0.61 | n/a |
Course of study | ||||||
 Medicine only | 38 | 20565 | 37.42% | 30.77 | 44.06 | 99.83%* |
 Mixture of courses | 23 | 64,814 | 37.40% | 31.95 | 42.86 | 99.33%* |
 Nursing only | 6 | 2742 | 48.53% | 34.05 | 63.00 | 98.43* |
 Dentistry only | 2 | 376 | 58.76% | 53.93 | 63.59 | n/a |
World Bank classification | ||||||
 High income | 29 | 34854 | 36.22% | 29.50 | 42.94 | 99.60%* |
 Upper middle income | 30 | 62369 | 35.95% | 31.10 | 40.80 | 99.78%* |
 Lower middle income | 22 | 8527 | 50.13% | 38.30 | 61.95 | 99.42%* |
 Low income | 2 | 660 | 29.39% | 25.91 | 32.86 | n/a |
Study conducted during COVID-19 pandemic | ||||||
 Pre-pandemic | 79 | 66685 | 40.42% | 35.04 | 45.80 | 99.85%* |
 During pandemic | 4 | 42272 | 24.34% | 16.18 | 32.50 | 99.78%* |